OBJECTIVES: Diabetes prevalence has grown rapidly in China. As the largest epidemiology and clinical outcomes assessment program, China Cardiometabolic Registries (CCMR), has been designed to establish systemic evaluation on disease progression and influencing factors. The Nationwide Assessment of CVD Risk Factors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients with type 2 Diabetes (T2D) (CCMR-3B) was one of the CCMR studies and was conducted to assess the clinical outcomes of current treatment patterns. METHODS: This was a cross sectional, observational study. Patients were recruited from community (tier 1), regional (tier 2), and teaching hospitals (tier 3) from all 6 major geographic regions in China, by cardiologists, nephrologists and endocrinologist, and internal medicine.  RESULTS: A total of 5099 T2D patients was included for this analysis. Across all hospitals, 55% and 34% of the patients had hypertension (HTN) or dislipidemia (DYLP), respectively, while 33% had neither. No difference was found between hospitals regarding the proportion of patients reaching target control (HbA1C<7.0%, BP<130/80 mmHg, LDL<2.6 mmol/L) in those who also have HTN or DYLP (ranging from 4.4 % to 6.6% for the HTN group and 6.9% to8.0% for the DYLP group). However a trend toward a better HbA1C control in patients without HTN or DYLP (diabetes only) in larger hospitals was seen (10.7%, 11.2%, 15.4% in tier 1, 2 and 3 hospitals, respectively). A trend toward more use of multiple oral anti-diabetic drugs and insulin was also seen in larger hospitals. CONCLUSIONS: Better HbA1c control seen in larger hospitals was associated with more aggressive use of antidiabetic treatment. The control of cardiovascular risk factors, blood glucose, blood pressure, and blood lipid, in diabetes patients with HTN or DYLP remains to be challenging in all hospital settings.